{"data":{"id":"us/42-cfr-427.504","jurisdiction":"us","citation":"42 CFR 427.504","heading":"Manufacturer access to Rebate Reports.","body":"(a) General. CMS will establish a method and process for a manufacturer of the Part B rebatable drug to:\n(1) Access the manufacturer's Rebate Report as set forth in §§ 427.501 and 427.502, including any report of reconciled rebate amount as set forth in §§ 427.501(d) and 427.502(c)(2)(ii);\n(2) Submit a Suggestion of Error as set forth in §§ 427.502(c)(1)(ii) and (c)(2)(i) and 427.503; and\n(3) Pay a rebate amount as set forth in § 427.505.\n(b) [Reserved]","path":["Title 42—Public Health","CHAPTER IV—CENTERS FOR MEDICARE \u0026 MEDICAID SERVICES, DEPARTMENT OF HEALTH AND HUMAN SERVICES","SUBCHAPTER B—MEDICARE PROGRAM","PART 427—MEDICARE PART B DRUG INFLATION REBATE PROGRAM","Subpart F—Reports of Rebate Amounts, Reconciliation, Suggestion of Error, and Payments"],"source_url":"https://www.ecfr.gov/api/versioner/v1/full/2026-08-25/title-42.xml","current_through":"2026-08-25","vintage":"","retrieved_at":"2026-08-27T02:26:11Z","sha256":"e14ac4aa027c8ca41e47d8dcba22433ba3b362a0e614df39d2a1ea39ef767f63","source_id":"us-cfr","stale":true,"prev":"us/42-cfr-427.503","next":"us/42-cfr-427.505"},"notice":"GroundRules: Original legal text. Not legal advice."}